منابع مشابه
Comparative assessment of clinical response in patients with rheumatoid arthritis between PF‐05280586, a proposed rituximab biosimilar, and rituximab
AIMS To evaluate potential differences between PF-05280586 and rituximab sourced from the European Union (rituximab-EU) and USA (rituximab-US) in clinical response (Disease Activity Score in 28 Joints [DAS28] and American College of Rheumatology [ACR] criteria), as part of the overall biosimilarity assessment of PF-05280586. METHODS A randomised, double-blind, pharmacokinetic similarity trial...
متن کاملTarget-directed development and preclinical characterization of the proposed biosimilar rituximab GP2013
Biosimilar development involves a target-directed iterative process to ensure a similar product to the originator. Here we report the preclinical development of the proposed biosimilar rituximab (GP2013). Post-translational modifications and bioactivities of GP2013 versus originator rituximab were engineered and monitored to ensure similar pharmacological profiles. Antibody-dependent cellular c...
متن کاملPamela Emmerling: Ärztliche Kommunikation; Als Erstes heile mit dem Wort ....
Pamela Emmerling, an educator and psychotherapist, has been active for many years as coach and university instructor in connection with the field of medicine (medical associations, medical training courses, hospital and practice consulting, etc.). Her new book, Ärztliche Kommunikation, is not only suitable for those working in hospitals, but also those in private practice. Although patient simu...
متن کاملThe Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
INTRODUCTION New biosimilars of monoclonal antibodies are anticipated to bring significant cost savings and increase access to treatment. The rituximab biosimilar CT-P10 has recently been approved in Europe in all indications held by reference rituximab (RTX), including rheumatoid arthritis, non-Hodgkin's lymphoma, and chronic lymphocytic leukemia. We analyzed the budgetary impact of the introd...
متن کاملErratum to: The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries
The authors of this manuscript have noticed a mistake since publication of their manuscript. In the original publication, the ‘‘Total RTX consumption per patient (mg)’’ in Table 1, was incorrectly published as 1814.00. The correct value of ‘‘Total RTX consumption per patient (mg)’’ should read as 11,814.00. Open Access. This article is distributed under the terms of the Creative Commons Attribu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: MMW - Fortschritte der Medizin
سال: 2017
ISSN: 1438-3276,1613-3560
DOI: 10.1007/s15006-017-9858-0